SF
NBIX icon

Synovus Financial’s Neurocrine Biosciences NBIX Stock Holding History

Synovus Financial’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-240
Closed -$20K – 1925
2020
Q1 		$20K Buy
240
+185
+336% +$18.1K ﹤0.01% 1373
2019
Q4 		$6K Buy
+55
New +$5.76K ﹤0.01% 1286

Other funds holding NBIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Synovus Financial's NBIX Position: Q2 2020 in Review

Synovus Financial sold out of Neurocrine Biosciences (NBIX) in Q2 2020, closing a stake of 240 shares — an estimated $20K sold.

Synovus Financial first reported a position in NBIX in Q4 2019 and held it in 2 quarters. The position peaked at $20K in Q1 2020. 418 funds tracked by Wall St. Rank hold NBIX as of Q2 2020.

  • Synovus Financial reported no remaining Neurocrine Biosciences position as of Q2 2020 after selling out during the quarter.
  • Synovus Financial sold 240 Neurocrine Biosciences shares in Q2 2020, an estimated $20K.
  • Synovus Financial first reported a position in Neurocrine Biosciences in Q4 2019 and held it in 2 quarters.
  • Synovus Financial's Neurocrine Biosciences position peaked at $20K in Q1 2020.
  • 418 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2020.

Based on Synovus Financial's 13F filing for Q2 2020, filed 10 Aug 2020.